You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

Guidelines & Advice

About Guidelines Email Guidelines Team

Immunotherapy

The guidelines and other documents available here provide recommendations related to immunotherapy for people affected by cancer in Ontario.

Displaying Guidelines

11 Items

An Endorsement of the ASTRO/ESTRO 2023 Guideline for the Treatment of Patients with Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer

Document Status: Current
ID: GL END 7-24

Updated

Nov 2024

Enhancing the Delivery of Take-Home Cancer Drugs in Ontario

Document Status: Current

Mar 2019

Follow-Up Model of Care for Cancer Survivors: Recommendations for the Delivery of Follow-up Care for Cancer Survivors in Ontario

Document Status: Current
ID: N/A
Version: N/A

Mar 2019

Immune Checkpoint Inhibitor Toxicity Management Clinical Practice Guideline

Document Status: Current
Version: 1

Mar 2018

Oncology Caregiver Support Framework

Document Status: Current
ID: N/A
Version: N/A

Oct 2019

Organizational Guidance for the Care of Patients with Central Nervous System Tumours in Ontario: Consensus Recommendations

Document Status: Current
ID: GL 9-11

Oct 2024

Pandemic Planning Clinical Guideline for Patients with Cancer

Document Status: Current
Version: 2

Dec 2021

Position Statements for Nursing Practice in Cancer Care

Document Status: Current
Version: 2

May 2021

Recommendations for the Delivery of Psychosocial Oncology Services in Ontario

Document Status: Current

Apr 2018

Systemic Adjuvant Therapy for Adult Patients at High Risk for Recurrent Melanoma

Document Status: Current
ID: 8-1
Version: 6

Mar 2024

T-Cell Engaging Antibodies: Management of Cytokine Release Syndrome (CRS) and Immune Effector-Associated Neurotoxicity Syndrome (ICANS)

Document Status: Current

Updated

Mar 2025